首页> 外文期刊>Acta Poloniae Pharmaceutica: Durg Research >Influence of combined therapy with rosuvastatin and amitriptyline on the oxidation-reduction status in rats
【24h】

Influence of combined therapy with rosuvastatin and amitriptyline on the oxidation-reduction status in rats

机译:罗苏伐他汀与阿米替林联合治疗对大鼠氧化还原状态的影响

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The aim of the present study was to assess the impact of combined therapy with rosuvastatin (10 mg/kg) and amitriptyline (10 mg/kg) on oxidation-reduction status in the blood of rats. After 2-week application of drugs alone or their combination, the activity of glutathione peroxidase (GPX), glutathione reductase (GR) and total antioxidant status (TAS) were determined. It was noticed that combined therapy with rosuvastatin and amitriptyline significantly increased the activity of GPX in comparison to the group receiving only rosuvastatin and decreased the activity of GR in comparison to groups receiving only rosuvastatin or amitriptyline. However, the activity of these enzymes as a result of combined therapy was placed in the level of the control groups. Our studies indicated that the combined therapy with both drugs caused an increase of TAS compared to the groups of animals receiving only one of these drugs. The results indicate on the oxidation-reduction balance and increasing the antioxidant status in rats treated with rosuvastatin and amitriptyline.
机译:本研究的目的是评估瑞舒伐他汀(10 mg / kg)和阿米替林(10 mg / kg)联合治疗对大鼠血液中氧化还原状态的影响。单独或联合使用药物2周后,确定了谷胱甘肽过氧化物酶(GPX),谷胱甘肽还原酶(GR)和总抗氧化剂状态(TAS)的活性。注意到与仅接受瑞舒伐他汀的组相比,罗苏伐他汀和阿米替林联合治疗显着增加了GPX的活性,而与仅接受瑞舒伐他汀或阿米替林的组相比,GPX的活性降低了。但是,由于联合治疗,这些酶的活性被置于对照组的水平。我们的研究表明,与仅接受其中一种药物的动物组相比,两种药物的联合治疗导致TAS升高。结果表明,用瑞舒伐他汀和阿米替林治疗的大鼠具有氧化还原平衡并增加了其抗氧化状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号